https://wiki.tiffa.net/w/index.php?action=history&feed=atom&title=Translations%3ADiabetes_medication%2F53%2Fen 2026-07-08T19:00:46Z Revision history for this page on the wiki MediaWiki 1.43.0 https://wiki.tiffa.net/w/index.php?title=Translations:Diabetes_medication/53/en&diff=110597&oldid=prev 2024-02-04T03:09:12Z

<p>Importing a new version from external source</p> <p><b>New page</b></p><div>{| class=&quot;wikitable sortable&quot;<br /> |-<br /> ! colspan=&quot;5&quot; style=&quot;background-color: #CCEEEE;&quot; | Comparison of anti-diabetic medication<br /> |-<br /> ! Drug class<br /> ! Mechanism of action<br /> ! Advantages<br /> ! Disadvantages<br /> |-<br /> | [[Sulfonylurea]]s ([[glyburide]], [[glimepiride]], [[glipizide]])<br /> | Stimulating insulin release by pancreatic [[beta cell]]s by inhibiting the [[ATP-sensitive potassium channel|K&lt;sub&gt;ATP&lt;/sub&gt; channel]]<br /> |<br /> * Inexpensive<br /> * Fast onset of action<br /> * No effect on [[blood pressure]]<br /> * No detrimental effect on [[low-density lipoprotein]]<br /> * Lower risk of [[Human gastrointestinal tract|gastrointestinal]] side effects than metformin<br /> * Convenient dosing<br /> |<br /> * Cause an average of 2–5&amp;nbsp;kg [[weight gain]]<br /> * Increase the risk of hypoglycemia<br /> * Glyburide increases risk of [[hypoglycemia]] slightly more compared to glimepiride and glipizide</div>

FuzzyBot